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1. introduction
China is becoming a strategic player in the pharmaceutical market, both 
as a consumer country and as an r&d industrial platform (Spigarelli, Wei 
2012).
The Government has been embracing a large reform in the healthcare 
system to upgrade the quality and coverage of healthcare assistance of Chi-
nese people. Multiple strategies are promoted, both on the demand and on 
the offer side. The Twelfth Five-Year Plan for Health Sector Development is 
a milestone in this process 1. A key issue in the strategy towards a new health-
care system is related to the transformation of the Chinese pharmaceutical 
industry (Ministry of Health prc, 2013, p. 130): the Government is planning 
to build an innovative system, led by research-based companies, where inte-
gration of local firms with international companies is encouraged and where 
a new – strong – role for Traditional Chinese Medicine is promoted. Foreign 
investments are supported, especially in high-end pharmaceutical products 
The research leading to these results has received funding from the People Programme (Marie 
Curie Actions) of the European Union’s Seventh Framework Programme fp7/2007-2013/ under 
reA grant agreement no 612589. The publication does not necessarily reflect the opinion of the eu.
Authors are thankful to ItalyChina Foundation, CeSIF, for data provided.
1 The Plan was formulated according to The Twelfth Five-Year Plan for the National 
Economic and Social Development of the People’s Republic of China, Opinions of the cpc 
Central Committee and the State Council on Deepening Health Care Reform, and Notice 
of the State Council on Printing and Distributing the Strategy and Implementation Plan of 
Deepening the Health Care Reform during the «Twelfth Five-Year Plan» Period (see http://
www.wpro.who.int/health_services/china_nationalhealthplan.pdf).
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through the New Catalogue of Investments (cccmhpie, 2011), but at the 
same time, the development of national global players is encouraged (Mof-
com, 2012).
To grasp knowledge, know how and best practices, China is attracting 
not only the manufacturing and marketing division of foreign firms, but it is 
also promoting the transfer in China of some of their critical business opera-
tions, core technologies and research development (Wilsdon, Fiz 2013).
The growth of the size of the «industry» is also due to an increased order 
in the market, to the exit of small and irregular competitors, to more stability 
in drug regulation and to an improved intellectual property (ip) protection. ip 
issues, in particular, play a fundamental role for the development of the mar-
ket. In recent years, pharmaceutical is among the industrial sector which has 
applied the highest number of patents in China: domestic firms are actually 
the main actors, but patent applications and granted patents of foreign enter-
prises are increasing as well. 
Despite the dramatic growth of the market, and the expected profitabil-
ity deriving from a booming demand, there are also some evidence of how 
challenging and risky this market could become for foreign investors. Foreign 
firms must cope with some persistent problems in China’s healthcare system: 
under-compensated doctors, insufficient reimbursement to hospital adminis-
trators, unclear regulation for drug discovery and clinical trials, high level of 
bribery. 
The aim of the paper is to give a general overview of the current charac-
teristics of the Chinese pharmaceutical market, of its main trends, as well as 
of main changes and expected evolution of the demand and of the supply in 
the industry. We also look at the balance between foreign and national firms’ 
position in the market, in term of Western interests for Chinese traditional 
knowledge embedded in Traditional Chinese Medicine (tcm) as well. We try 
to build a general picture of the industry and of main competitors. 
The paper is a first research output of a wide research project, founded 
by the European Commission, aiming at analysing cooperation opportunities 
and potential synergies for Europe and China in the healthcare sector 2. Us-
ing an interdisciplinary approach, researches in the project are focusing on 
policies issues (at national and local level), on legal issues, on medical prac-
tices, as well as on trade and fdi opportunities in the healthcare related busi-
nesses. Understanding the Chinese pharmaceutical market features is a start-
ing point for the analysis of the extent, determinants and characteristics of 
trade and fdi flows between Europe and China.
2 The project title is China and Europe taking care of healthcare solutions – chetch. See 
www.chetch.eu. 
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The paper is structured as follows. Paragraph 2 is focused on main trends 
in the Chinese pharmaceutical market: consumptions, production, import 
and export flows. Features of the industry and main competitors are de-
scribed in Paragraph 3, while Paragraph 4 is about tmc specific market. Par-
agraph 5 analyses the motivation of the increasing presence of global phar-
maceutical players in China. Paragraph 6 is focused on ip trends and on the 
role of national firms vs foreign competitors. 
Before starting the analysis, a clarification is fundamental. The Chinese 
pharmaceutical market is a comprehensive industry, for manufacturing and 
sale of: synthetic chemicals and drugs, the so-called Western drugs, includ-
ing otc – over the counter medicine and prescription medicine; traditional 
Chinese medicines (tcm); medical devices, apparatus and instruments; hy-
giene materials; and pharmaceutical machinery. In this paper we focus only 
on Western and tcm drugs, for which the patenting issues are more relevant 
and seem to fit best our research goals.
2. the changing internal demand for pharmaceutical products
China is the world’s third-largest pharmaceutical market in term of sale 
(ims, 2010; Economic Research Institute, 2012), but it should become the 
second by 2020, behind only the United States. Several data and trends can 
help understand the speed and scope of changes undergoing in China. 
Expenditure on health care is expected to increase from 4.7 per cent of 
gdp to 6 per cent/7 per cent in the next few years. China should reach a 
total amount of healthcare expenditure of 705.74 dollar by 2015, while per 
capita expenditure should be set at a level of 437 dollars in 2016, compared 
to 109.5 dollars in 2007 (Deloitte, 2011, p. 10). Following latest projec-
tions, China’s health-care spending should triple to 1 trillion dollars by 2020 
(Burkitt, Whalen 2013). 
As a result of such facts and figures, the Chinese pharmaceutical market 
is becoming increasingly attractive to Western firms. It is considered one of 
the World’s most important emerging pharmaceutical areas (Business Moni-
tor International Ltd, 2011).
At the moment, sales from generics dominate the market (61.4 per cent 
of the market share in 2009), but newly patented products are expected «to 
gain shares from a huge and rapidly growing absolute value market» (Jan-
Willem, 2011, p. 2). 
Data on imports of pharmaceutical products show a strong expansion 
(+195 per cent of the value of flows from 2006 to 2010), and in parallel, ex-
ports are accelerating (+135 per cent over the same period) (see fig. 1)
In 2013, exports (+6.8 percent) and imports (15.2 percent) in the indus-
try totalled 89.7 billion dollars (Xinhua, 2014).
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From a demand-side perspective, demographic factors can be considered 
as one of the most relevant drivers of the growth of China’s pharmaceutical 
market. 
China is the most populous country in the World, thus resulting in a 
large size potential market. At the same time, the population is ageing, also 
as a consequence of the one-child policy. Many observers consider this issue 
the country’s Achille heel: the total fertility rate is well below the replacement 
rate 3, and the share of young population is decreasing rapidly 4. Elderly peo-
ple require appropriate, specific and long-term health care assistance, whose 
costs are much higher compared to those absorbed by young country popu-
lation. Estimated increase of drug prescription market as a result of ageing 
trends is between 23 per cent and 40 per cent, while the increase for the otc 
market should be between 40 per cent and 50 per cent by 2016 compared to 
2011 (Deloitte, 2012, p. 7). 
The higher sensitivity of Chinese people on healthcare services and prod-
ucts can also be related to higher living standards (Yuanjia, 2007, p. 296). As 
3 «Over the past 30 years, China’s total fertility rate - the number of children a woman 
can expect to have during her lifetime – has fallen from 2.6, well above the rate needed to 
hold a population steady, to 1.56, well below that rate. Because very low fertility can become 
self-reinforcing, with children of one-child families wanting only one child themselves, China 
now probably faces a long period of ultra-low fertility, regardless of what happens to its one-
child policy» (The Economist, April 21st 2012).
4 People above the age of 60 now represent 13.3 per cent of the total, up from 10.3 per 
cent in 2000. In the same period, those under the age of 14 declined from 23 per cent to 17 
per cent» (The Economist, May 5th 2011).
fig. 1. Import and Export trade in Medical & Pharmaceutical Product sector (data in million us dollars)
Source: Own calculation on data provided by ceic data base (http://www.ceicdata.com/countries/
china), by CeSif, Fondazione Italia Cina.
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the income per capita heightens, people can put more money in taking care of 
their health needs, upgrading the typical expenditure structure of consump-
tion from basic good to more sophisticated goods. More and more high qual-
ity healthcare services are going to be requested by healthier Chinese people.
Urbanization is another important aspect to take into account: mass mi-
gration to the cities, from the agricultural areas, is resulting in a growing de-
mand for pharmaceuticals (Yuanjia, 2007, p. 296). People is becoming more 
used to new lifestyles and has an easy access to retail pharmacies. The strong 
commitment made by the Government towards the upgrading of rural infra-
structure should supports this trend (Deloitte, 2011, p. 4).
Beside from the demographic perspective, the rising consumption of 
pharmaceuticals is also related to the evolution of the typical needs/requests 
of the Chinese healthcare consumer. High longevity, combined with environ-
mental and pollution problems are increasing chronic diseases like respirato-
ry illnesses, cancer, diabetes, as well as obesity (Jan-Willem, 2011). New life-
styles are considered the cause of those diseases, sometimes called «lifestyle 
disease» – for which the use of lifestyle drugs are booming. Consumption of 
otc is increasing as well, as a result of a new attitude towards self-medica-
tion. As reported by several surveys (Yuanjia, 2007, pp. 297-298), self medi-
cation is becoming more and more popular among Chinese people (Deloitte, 
2011, p. 15). Since without a medical prescription patients can only have ac-
cess to otc drugs, a relevant increase in this market is expected in the future.
Last sign of the evolving Chinese consumer habits is the booming sales of 
drugs on line, because of the increasing attitude towards online shopping and 
the diffusion of the internet (Cripps, 2013) 5. 
The cultural and social revolution that is taking place in the healthcare 
habits of Chinese people has a lot to do with institutional factors. In 2009 
the government launched new plans to reshape the National health-care sys-
tem (Rein, 2009). According to the Guidelines on Deepening the Reform of 
Health-care System (Freeman, Lu Boynton, 2011), the first phase of the re-
form aims to: increase the Basic Medical Insurance (bmi) to reach a 90 per 
cent of population coverage by 2011; revise the reimbursable medicine un-
der bmi, i.e. of the essential drugs list; set a more restrict regulation on prices 
5 China has more online shoppers (193 million) than any other country in the world. us 
has 170 million online consumers (Jingting, 2012). «By 2015, China will add nearly 200 million 
users, reaching an Internet population of more than 700 million-almost double the combined 
number of Japan and the US» (Michael et al., 2012). As a result of the booming on line sales, 
the On 8 January 2013, the State Food and Drug Administration released a Report concerning 
the results of its investigations into online pharmaceutical trading activities conducted 
pursuant to the Notice to Further Enhance Supervision and Administration over Internet Drug 
Information Services and Internet Drug Trading Services to Severely Crack Down on the Illegal 
Release of False Drug Information and Drug Sales (sfda, 2012, n. 62, 24th February 2012).
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by the National Development and Reform Commission (Deloitte, 2011, p. 
3). The second phase of the reform should bring into effectiveness a univer-
sal health care system, providing «safe, effective, convenient and affordable» 
health services to urban and rural residents (Freeman, Lu Boynton, 2011). 
3. emerging trends in the chinese pharmaceutical industry
The 12th Five-Year Plan (2011-2016), released in 2011, has also put 
strong attention to pharmaceutical industries (Tung, 2011; Deloitte, 2010, 
2011; who, 2012, Wong et al., 2014) 6. To expand health coverage and to re-
duce inefficiency in healthcare delivery, the Government is tackling the drug 
market. Specific actions are carried out to cut drug prices, reduce hospital 
reliance on drug revenues, increase the quality of coverage and diversify the 
insurance scheme, strengthen local companies (Wong et al., 2014, pp. 4-7).
On Jan 18th 2012, the Ministry of Industry and Information Technology 
released «the Pharmaceutical Industry «12th Five-Year» Development Plan». 
Eight main objectives are targeted for the industry, ranging from reinforce-
ment and concentration, improved managerial and quality standards, to en-
hance international competitiveness through export and international ven-
tures (cccmhpie, 2012).
Healthcare reforms, while affecting consumptions, habits, and behaviours 
of Chinese people are therefore having a significant impact on the industry, 
which is still highly fragmented (Yuanjia et al., 2007) and with strong rivalry. 
National firms compete and cooperate with foreign companies that have a 
direct presence in the market 7. The three major firms – one Chinese and two 
big Western multinationals – share only 10 per cent of the market. Yangtze 
River Pharmaceutical Group is the leading player (3.6 per cent of the mar-
ket’s value), AstraZeneca plc controls 3.4 per cent and Pfizer Inc. 3.0 per 
cent (Datamonitor, 2011, p. 8).
6 On October 8th 2012, the Information Office of the State Council released the Twelfth 
Five-Year Plan for Health Sector Development. The five-year plan builds upon three previous 
documents, the Twelfth Five-Year Plan for the National Economic and Social Development 
of the People’s Republic of China, Opinions of the cpc Central Committee and the State 
Council on Deepening the Health Care System Reform, and the Notice of the State Council 
on Printing and Distributing the Strategy and Implementation Plan of Deepening the Health 
Care System Reform during the 12th Five-Year Plan Period. See http://www.uschinahcp.org/
twelfth-five-year-plan-health-sector-development#sthash.1NgeZZuH.dpuf.
7 From a geography perspective, most firms are located in the south-eastern zone, 
including two well developed areas (Zhejiang and Guandong provinces) and three 
underdeveloped areas (Hebei province, Heilongjiang province and Sichuan province). The 
motivation of this concentration can be found in the economic factors that draw the growth in 
last years. (Yuanjia et al., 2007, p. 19).
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Distribution is fragmented, inefficient and with poor transparency. As a re-
sult of the 12th Five year plan actions, a considerable effort of concentration 
is in place. By promoting national mergers and acquisitions the government is 
trying to build an effective distribution system based on few leading national 
companies, and some regional drug distribution firms (Deloitte, 2012, p. 16). 
Above this general picture, in recent years, Chinese pharmaceutical market 
has made remarkable development, and its scale has increased rapidly. In 2010, 
the gross output of Chinese pharmaceutical market was 183.57 billion dollars: 
118.25 billion dollars more compared to 2005. The industrial added value was 
69.25 billion dollars, with an annual growth rate of 15.4 per cent, larger than 
that of gdp and national industrial average growth. Total profit increased as 
well, at a rate higher than that of production value (Ministry of Industry and 
Information Technology, 2012). What’s more, from 2000 to 2010, the num-
ber of pharmaceutical enterprises above the «designated size» 8 increased from 
3,301 to 7,039; the value added tax was $ 1.39 billion in 2000, and increased to 
8.08 billion dollars in 2010. From 2000 to 2010, revenues from principal busi-
ness changed from 19.66 billion dollars to 168.66 billion dollars (tab. 1). 
The number of firms has quite doubled from 2000 to 2010 and their 
scale has been also increasing. State-owned enterprises, foreign enterprises 
and private enterprises compete in the market (see tab. 2). Even if the num-
ber of private firms has experienced a sharp increase, their average size is 
8 As stated by the National Bureau of Statistics of China, the relevant size is reached 
when revenue from principal business is more than 5 million yuan. 5 million yuan equal to 
0.7386 million dollars in 2010.
tab. 1. Chinese manufacture firms in the pharmaceutical industry, above designated size 
Year N. of 
enterprises 
Gross 
industrial 
output 
value ($100 
millions)
Total assets 
($100 
millions)
Revenue from 
principal 
business 
($100 
millions)
Total profits 
($100 
millions)
Value Added 
Tax Payable 
($100 
millions)
Annual 
average n. of 
employees 
(10,000 
persons)
2000 3301 215.18 338.10 196.59 16.50 13.94 83.00
2001 3488 246.57 396.41 232.50 20.30 16.03 82.00
2002 3681 287.36 446.25 275.46 24.33 18.14 82.00
2003 4063 349.16 521.50 332.33 31.37 20.35 115.40
2004 4397 579.70 388.19 33.78 22.41 118.51
2005 4971 518.87 677.49 490.72 41.29 26.77 123.44
2006 5368 629.59 769.77 591.94 46.73 30.68 130.28
2007 5748 836.65 909.59 784.74 76.44 40.47 137.34
2008 6524 1133.89 1134.90 1065.83 114.17 57.34 150.75
2009 6807 1382.42 1367.49 1330.26 145.51 66.39 160.48
2010 7039 1734.44 1642.13 1686.58 196.63 80.82 173.17
Source: China Statistical Yearbook, several years (http://www.stats.gov.cn/).
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much lower than soes and foreign firms. soes, on their side, have been ex-
periencing a period of reorganization and rationalization: their number de-
creased from around 1.500 to around 500, but their average size grew signifi-
cantly, as well as their gross domestic output. 
Pushed by factors as market growth, technical progress, increased invest-
ment and mergers and reorganization initiatives, some large-scale enterprises 
are appearing in China and they are becoming leaders in basic drugs sup-
ply. There was only 1 pharmaceutical firm with more than 10 billion yuan 
(1.22 billion dollars) sale proceeds in 2005, while in 2010 they were 10. In 
2010, 1,125 out of the 7,039 pharmaceutical firms in the market were large 
and medium-sized, controlling 694.8 billion yuan (102.64 billion dollars) of 
the pharmaceutical industrial output value (59.17 per cent of total value) 9. 
Pharmaceutical enterprises with more than 5 billion yuan (0.61 billion dol-
lars) sales were 17 in 2010, while only 3 in 2005 (Ministry of Industry and 
Information Technology, 2012). Among them, Yangtze River Pharmaceutical 
Group, Harbin pharmaceutical Group, China Shijiazhuang Pharmaceutical 
Company, TongRenTang, Guangzhou Pharmaceuticals Corporation, Weigao 
Holding Co. Ltd are gaining market shares. 
At the same time, new enterprises, such as Jiangsu Hengrui Medicine 
Co., Zhejiang Hisun Pharmaceutical Co. Ltd., Tasly Group, Shineway Phar-
maceutical Group, Mindray, are developing rapidly. Some backbone enter-
prises, such as China National Pharmaceutical Group Corporation, Shang-
hai Pharmaceutical Co.,Ltd., Sino-Swed Pharmaceutical Corp.Ltd., are also 
growing rapidly by merger and acquisition, achieving integration of industry 
chain, enhancing their competitiveness. 
Enterprises listed in table 3 were the top 20 firms in Chinese pharmacy 
market. Yangtze River Pharmaceutical Group is the first as for prime operat-
ing revenue, while Shanghai Pharmaceutical (group) Co. Ltd had most gross 
assets. Looking at total profit, China National Pharmaceutical Group Corpo-
ration ranked first.
The presence of foreign enterprises in China is increasing, as well as their 
size. From the absolute value of indicators, we can find that there were only 
542 enterprises in 2000, while in 2010 they were 1,140. The total assets they 
hold moved from 6.4 to 44.34 billion dollars in 2010. In 2010, revenues from 
principal business reached 44.77 billion (ten times of that in 2000), while to-
tal profit was about 6 billion in 2010 (15 times of that in 2000) (tab. 4).
9 Large-sized industrial enterprises means that the number of employed persons is more 
than 2000, the sale revenue is more than 300 million yuan (44.31 million dollar in 2010), the 
total assets is more than 400 millions yuan (59.09 million dollars in 2010). Medium-sized 
Industrial Enterprises means that the number of employed persons is between 300 and 2000, 
the sale revenue is between 30 and 300 million yuan (4.43-44.31 million dollar in 2010), the 
total assets is between 40 and 400 million yuan (5.91-59.09 million dollars in 2010).
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In 2010, firms from abroad produced 27.01 per cent of gross industrial 
output value, 26.55 per cent of prime operating revenue, 30.89 per cent of 
total profit, and 27.1 per cent of total assets (tab. 5). Anyway, despite the 
importance of foreign companies, their share in the market is not overtaking 
national firms, that are keeping their role and competitive position.
tab. 3. Financial and economic data: ranking the top 20 firms in 2011 
Ranking Prime operating revenue Gross assets Total profit
1 Yangtze River Pharmaceutical 
Group
Shanghai Pharmaceutical 
(group) Co., Ltd.
China National Pharmaceuti-
cal Group Corporation
2 Xiuzheng Pharmaceutical 
Group Co. Ltd.
China Shijiazhuang Pharma-
ceutical Company
Weigao Holding Company 
Limited
3 Shanghai Pharmaceutical 
(group) Co. Ltd.
Tasly Group Shanghai Pharmaceutical 
(group) Co., Ltd.
4 Harbin pharmaceutical group Harbin pharmaceutical group Shandong Buchang Pharma-
ceutical Co., Ltd. 
5 China Shijiazhuang Pharma-
ceutical Company
Kangmei Pharmaceutical Co., 
Ltd.
Yangtze River Pharmaceutical 
Group
6 Tasly Group China National Pharmaceuti-
cal Group Corporation
nhu Group Co., Ltd.
7 Weigao Holding Company 
Limited
Weigao Holding Company 
Limited
Harbin pharmaceutical group
8 Yunnan Baiyao Group Com-
pany Limited
Yangtze River Pharmaceutical 
Group
Yunnan Baiyao Group Com-
pany Limited
9 China National Pharmaceuti-
cal Group Corporation
Sichuan Kelun Pharmaceuti-
cal Co., Ltd.
Tasly Group
10 Guangzhou Pharmaceuticals 
Corporation
Qilu Pharmaceutical Co., Ltd. Qilu Pharmaceutical CO., 
Ltd.
11 Bayer Group Zhejiang Jianfeng Pharmaceu-
tical Holdings
Hangzhou Sainuofei Anwan-
te Minsheng Pharmaceutical 
Co., Ltd.
12 Taiji Group Co., Ltd. Xiuzheng Pharmaceutical 
Group Co., Ltd.
Guangzhou Pharmaceuticals 
Corporation
13 Northeast Pharmaceutical 
(group) Co., Ltd.
Guangzhou Pharmaceuticals 
Corporation
Sichuan Kelun Pharmaceuti-
cal Co., Ltd.
14 Tianjin Zhongxin Pharma-
ceutical Group Corporation 
Limited
Yunnan Baiyao Group Com-
pany Limited
Kangmei Pharmaceutical Co., 
Ltd.
15 HeiLongJiang ZBD Pharma-
ceutical Co., Ltd.
Furen Medicine Group Zhejiang Medicine Co., Ltd.
16 Hangzhou Zhongmei Hua-
dong Pharmaceutical Co., 
Ltd.
nhu Group Co., Ltd. Jiangsu Hengrui Medicine 
Co., Ltd.
17 Sichuan Kelun Pharmaceuti-
cal Co., Ltd.
Taiji Group Co., Ltd. China Resources Dongeejiao 
Co., Ltd.
18 Beijing Double-Crane Phar-
maceutical Business Co., Ltd.
Zhejiang Hisun Pharmaceuti-
cal Co., Ltd.
Xiuzheng Pharmaceutical 
Group Co., Ltd.
19 Shanghai Roche Pharmaceuti-
cal Co., Ltd.
Northeast Pharmaceutical 
Group Co., Ltd
China Shineway Pharmaceuti-
cal Group
20 Shandong Buchang Pharma-
ceutical Co., Ltd.
Lunan Pharmaceutical Group 
Corporation
Jiangsu Chia-tai Tianqing 
Pharmaceutical Co., Ltd.
Source: Ministry of Industry and Information Technology of the People’s Republic of China, The 
rank of manufacture firms in the pharmaceutical industry in 2011,http://xfps.miit.gov.cn/n11293472/
n11295176/n11298973/14522230.html.
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Competition and rivalry among foreign firms and local companies is 
strongly affected by the changing scenario for proprietary technology. While 
in the past foreign multinationals hold patent protections of some of the 
world’s best-selling drugs 10, the situation is going to change rapidly as several 
drugs are going off patent within the next five years. This wave of patent-
ed drug expirations will boost manufacturing and sales of the related gener-
ics. Chinese state-owned firms and private companies will probably lead this 
market (Deloitte, 2012, p. 13), while foreign enterprises are supposed to play 
a more important role in non-generic drug industry.
10 As an example, in the insulin market Novo Nordisk, Eli Lilly and Sanofi controlled 
more than 90 per cent of the sales in 2010. See China Medical Association, The Development 
of Insulin Market in China, at http://www.chinamsr.com/2011/0124/21748.shtml.
tab. 4. Main Indicators of foreign firms in the Chinese market
Year N. unit Gross 
industrial 
output value 
($100 million)
Total assets 
($100 million)
Revenue from 
principal 
business 
($100 million)
Total profits 
($100 million)
Value added 
tax payable 
($100 million)
Annual average 
number of 
employees 
(10,000 persons)
2000 542 48.77 64.00 44.19 3.97 3.64 –
2001 568 54.76 70.11 51.05 4.69 4.17 –
2002 604 63.41 78.68 59.82 5.58 4.92 –
2003 701 76.84 93.34 69.67 8.37 5.29 16.92
2004 743 – 100.35 76.96 9.16 5.50 16.63
2005 890 127.92 145.06 118.05 12.60 8.27 22.62
2006 955 159.44 169.67 148.84 14.78 9.55 25.29
2007 1035 214.11 218.87 198.40 24.81 12.87 27.40
2008 1144 307.19 303.03 287.39 37.45 18.71 31.77
2009 1144 386.23 375.34 372.69 48.31 22.20 34.77
2010 1140 468.47 443.41 447.74 60.75 26.72 38.21
Source: China Statistical Yearbook, several years (http://www.stats.gov.cn/).
tab. 5. The role of foreign enterprises in the pharmaceutical market (percentage of total market)
Year Number of 
Enterprises
Gross industrial 
output value
Total assets Prime operating 
revenue
Total profit
2000 16.42 22.66 18.93 22.48 24.06
2001 16.28 22.21 17.69 21.96 23.08
2002 16.41 22.07 17.63 21.71 22.92
2003 17.25 22.01 17.90 20.97 26.69
2004 16.90 – 17.31 19.82 27.13
2005 17.90 24.65 21.41 24.06 30.52
2006 17.79 25.32 22.04 25.15 31.62
2007 18.01 25.59 24.06 25.28 32.46
2008 17.54 27.09 26.70 26.96 32.80
2009 16.81 27.94 27.45 28.02 33.20
2010 16.20 27.01 27.00 26.55 30.89
Source: China Statistical Yearbook, several years (http://www.stats.gov.cn/).
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4. traditional chinese medicine: a sector apart?
The pharmaceutical industry in China is peculiar also for the role played 
by tcm products and producers. Traditional Chinese medicines include pro-
prietary Chinese medicines, raw materials and ingredients, as well as herbal 
extracts. Even though Chinese people are more and more addressing their 
health problems using Western medicine; the majority of them still use tcm 
(who, 2011, p. 69). tcm is considered part of the Chinese culture and tradi-
tion, to be preserved, protected and promoted also abroad. 
The Government has been issuing several measures, in the past few years, 
to promote the development of a modern tcm industry, as well as the inte-
gration of tcm into the national health care system (who, 2011, p. 69). 2009 
was launched as tcm Hospital Management Year and several specific actions 
were promoted by the State Administration of Traditional Chinese Medi-
cine (satcm) to disseminate the advantages of tcm among people and prac-
titioners, as well as to improve quality, safety, and efficiency in the industry. 
In 2010, the Minister of Health identified some key priority actions for tcm 
development. Among them the need for «increasing policy support for tcm; 
strengthening research on key tcm issues and building capacity for tcm re-
search; establishing well-known tcm hospitals and departments; promoting a 
culture of tcm; and strengthening international cooperation and communica-
tion on tcm» (who, 2011, p. 69). 
The importance of tcm has been clearly recognized by The Twelfth Five-
Year Plan for Health Sector Development. «Actively develop traditional Chi-
nese medicine» is one of the key actions of the Plan. 
tcm is important both to support the organization and management of 
the new Chinese healthcare systems, and to promote national industry com-
petitiveness abroad. The Government aims to: improve legislation, informa-
tion and standards, in the light of a strong integration with western medicine; 
increase research and innovation in the tcm; strengthen the organization of 
delivery of tcm services system, from primary health facilities, retail pharma-
cies, to diagnosis services. 
Also, the development of a competitive tcm industry is considered a pri-
ority. Chinese firms are supposed to gain a competitive position at global 
level (The Twelfth Five-Year Plan for Health Sector Development, p. 12) and 
to expand their export propensity. The government is improving industrial 
standards to help companies deal with technology and patenting issues that 
arise in the international market, as well as to face trade barriers and other 
obstacles that Chinese firms encounter abroad. For China’s tcm exporters, 
the main challenges are technical standards, which are especially stringent 
for formulary tcms, and registration in developed markets (Jie, 2012). Many 
overseas authorities, as a result of a poor knowledge of tcm, apply the stand-
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ards relating to synthetic medicines to tcms. This means that chemical index-
ing and data garnered from clinical trials are needed. However, scientific re-
search into tcms, especially into compound formulary medicines, only started 
in the mid-1980s and so no long-running databases are available. 
In addition to those technical problems, new rules concerning market 
registration are also hindering Chinese companies’ strategies to enter interna-
tional markets 11. 
The Government is therefore supporting scientific research on many in-
gredients used in tcm, as well as the introduction of patent rights and mod-
ern applications for tcm-related products (pwc, 2009, p. 4). Several bodies, 
including Chambers of Commerce, government departments, research insti-
tutes and trading agencies are working to develop industry-supporting poli-
cies, such as the establishment of international trade guidance for traditional 
Chinese medicine (cccmhpie, 2012b). There is a lack of unified, systematic 
regulations to assess the safety, efficacy and the quality of tcm products. 
There are no national tcm standards or guidelines for tcm clinical trials: 
evidenced-based tcm product testing and research are still needed. Also the 
quality of tcm education needs to be strengthened, and the management and 
supervision of tcm institutions to improve the qualifications of tcm practi-
tioners and the correct use of tcm within the new national healthcare system 
(who, 2011, p. 69) (tab. 6).
After the release of the 12th five year Plan, the value of traditional Chinese 
medicine exported from China is expected to increase by more than 10 per-
cent a year. The demand for tcm in the international market increased from 
600 million dollars in 1996 to 1.8 billion dollars in 2010. The value of China’s 
exports of the medicine reached 2.33 billion dollars in 2011, with an increase 
of 36.2 percent from the year before. Chinese companies are trying to make 
prices more stable and modify the composition of the exports. During the past 
few years, the proportion of raw materials and ingredients among exports has 
decreased and that of herbal extracts has risen. Herbal extracts can be more 
profitable, as they are semi-processed products with more intense added value.
11 In Europe, the Herbal Directive (Directive 2004/24/ec) was adopted to facilitate the 
placing on the eu market of traditional herbal medicinal products. The Directive introduces 
a simplified procedure to allow the registration of traditional herbal medicinal products 
without requiring safety tests and clinical trials. The Directive gave a long transitional period 
of 7 years to register traditional herbal medicinal products that were already on the market on 
the date of entry into force of the Directive. The transitional period ended on 30 April 2011 
(see: http://ec.europa.eu/dgs/health_consumer/docs/traditional_herbal_medicinal_products_
en.pdf). Despite the efforts of the European Commission, the Directive failed its goals, as 
it is particularly unsuitable for multi-herb products. As a result, only few herbal products 
associated with tcm has been registered (Alliance for Natural Health, 2010).
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5. foreign investors tackling the chinese market
As shown in the previous paragraphs, foreign firms play an increasing 
role in China. Most of them have made collaborative partnerships with Chi-
nese companies to start manufacturing plants, business operations facilities, 
marketing divisions, and research facilities.
As a result of the Open Door Policy, China has been attracting huge flows of 
fdis and has become the first recipient of fdi among emerging market, the sec-
ond after the us in absolute term (unctad, wir, 2011). The Chinese pharmaceuti-
cal industry has been one of the most interesting target for foreign investors. At 
the end of 1998, there were 1,500 pharmaceutical firms with foreign ownership (Ji-
ang, 2005, p. 22). Since 2000, investments have nearly doubled (fig. 2). Large mul-
tinational groups from North America, Western Europe, and Asia were attracted 
to China, as a result of a more friendly and favourable business and institutional 
environment. Operating in the Chinese market is still considered high-risky, 
time-consuming and expensive compared to other emerging markets due 
to stringent regulations concerning safety and efficacy. Anyway, the interest 
tab. 6. Key Chinese players in the tcm industry
Top exporters of tcm companies, 2013 Branded tcm companies
1.  Ningming Import & Export Foreign Trade Gen-
eral Company of Guangxi 
1. Tianjin Zhongxin pharmaceutical group Co. Ltd.
2.  Beijing Green Jinke Biological Technology Stock 
Co., Ltd.
2. Lanzhou Foci pharmaceutical Co. Ltd.
3. Shanghai Tsumura Pharmaceutical Co., Ltd. 3. Heifei Golden deer Int’l Trading Co. Ltd.
4.  Jilin Lincun Chinese Medicine Development Co., 
Ltd.
4. Handan Moluodan pharmaceutical Co.
5. China Meheco Co., Ltd. 5. Guangxi Golden throat Co. Ltd.
6. Anhui Guangyintang Chinese Medicine Co., Ltd. 6. Gansu Meheco import and export Co. Ltd.
7. Ningbo Green-Health Pharma-ceutical Co., Ltd. 7. Tasly Group
8. Aodemei Biotechnology Co.,Ltd (Zhongshan) 8. Yilling Pharmaceutical
9. Zhangjiagang Maifu Biopharmaceuticals 9. Guandong Taiantang pharmaceutical Co. Ltd.
10.  Teck Soon Hong (Zhuhai) Flavours & Fragran-
ces Ltd.
10.  Fujian Xianzhilou Biological Science & Tech-
nology Co. Ltd.
11. Ganzhou Julong High-tech Industrial Co., Ltd. 11. Guangxi Yulin pharmaceutical group Co. Ltd.
12. Hunan Xinhua Food Company 12. Shineway pharmaceutical group Ltd.
13. Shenzhen Tsumura Pharmaceutical Co., Ltd. 13. Beijing Tongrentang group Co. Ltd.
14. Chenguang Biotech Group Co., Ltd. 14. Guilin Tianhe pharmaceutical Co. Ltd.
15.  Zhangzhou Pien Tze Huang Pharmaceutical Co., 
Ltd.
15.  Guilin Sanjin pharmaceutical Co. Ltd.
16. Shaanxi Jiahe Phytochem Co., Ltd. 16.  Guangzhou Baiyunshan Qixing pharmaceutical 
Co. Ltd.
17. Chongqing Kanghuai Trade Co.,Ltd
18. Guilin Layn Natural Ingredients Corp
19. Sichuan Xieli Pharmaceutical Co., Ltd 
20. Qujing Bohao Biotech Co., Ltd
Source: Chamber of Commerce for Import & Export of Medicines & Health Products (http://www.
cccmhpie.org.cn/English/).
517
for China is increasing and several factors can explain this trend. Based on 
the Dunning model (Dunning, Lundan 2008), key motivations can be high-
lighted.
5.1. Market seeking motivations
China is an important sales market for the internal, booming demand 
(Jiang, 2005) 12. As mentioned above, China is supposed to become the sec-
ond world largest pharmaceutical market by 2020, as a result of demographic 
changes, improved life standards, government actions. Upgrading health care 
behaviours and consumptions, Chinese people are changing their attitude to-
wards Traditional Chinese Medicine practices. Western medicines are consid-
ered more effective, especially as for life-saving drugs are concerned, antibiotics 
most of all. 
China is also strategic for Western companies to reach other nearby Asian 
emerging markets: while operating in the country, China can offer a logistic 
and commercial platform to penetrate them. 
12 In the study developed by Jiang (2005) on determinants of fdi into Chinese 
pharmaceutical market, the author found out that fdis were pushed mainly by China’s specific 
location factors. China’s market size and its potentials played the most important role. Other 
relevant motivations were: rapid economic development and growth, China’s Open Door 
Policy and relatively stable political conditions.
fig. 2. Inward fdi in China in the Medical & Pharmaceutical Product sector (million us dollars) 
Source: Own calculation on data provided by ceic data base (http://www.ceicdata.com/countries/
china), by CeSif, Fondazione Italia Cina.
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5.2. Efficiency seeking motivations
China is a market for delocalizing the production of high quality and 
price competitive raw materials. In some specific market segment (antibiot-
ics, cephalosporin o other high chemical substances), producing in China is a 
necessity. In the West, in fact, environmental and safety rules make it impos-
sible to set up fermentation and chemical plants associated with pharmaceu-
tical plants.
The delocalization phenomenon is not recent. Internationalization in Chi-
na began in the middle Eighties, when important pharmaceutical groups set-
tled fermentation plants in the North of the country to produce basic prod-
ucts for antibiotics. During the Nineties, production in China evolved, in-
cluding more sophisticated products/materials. Nowadays, China is the world 
leader in the production of pharmaceutical base materials, that are then 
re-imported in the Western markets to produce finished goods (medicines). 
This phenomenon could justify the huge increase in imports and exports vol-
umes, as well. 
5.3. Strategic asset seeking motivations: r&d providers
China is the frontier to develop applied research programs. Big players 
such as Novartis, Pfizer, Merck Serono, AstraZeneca, Roche have established 
research centres in China (Choi et al., 2011). The strategic idea is to leave 
good r&d departments in the country of origin to develop basic programs. 
The implementation phases and applied research activities are carried out in 
China, to reduce time for drug improvement and to cut costs. The core phas-
es related to market entry of a new drug are left in the West, partly because 
of stringent rules of trials required by the us and European agencies 13. All 
other, subsequent, trials and market extension activities are developed in Chi-
na, where skilled labour workforce, talented scientists and leading University 
research centres are available (Tung, 2011). 
China is more and more considered as a platform to develop innovative 
drugs (Choi et al., 2011, p. 6). Chinese Contract Research Organizations 
(cros) are considered the backbone of Chinese r&d. They support the phar-
maceutical and biotechnology industries on a contract basis, providing spe-
13 «The globalisation process of industry-sponsored clinical trials is growing. More and 
more study sites are located outside North America and Europe, especially phase III trials. 
From the latest analysis, there are now more phase II-III trial sites in the rest of the world 
(row) than Europe; 27.0 per cent versus 24.6 per cent, respectively. [...] The major emerging 
regions are still Eastern Europe, Asia and Latin America» (Karlberg, Speers 2010, p. 58).
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cific services: biopharmaceutical development, preclinical research, clinical 
research, as well as clinical trials management 14.
Chinese cros are expanding the activity of the value chain that they can 
serve, from early stage phases (genetic research, functional genomics, etc.), 
lead discovery (compound generation, screening, lead optimization), preclini-
cal trials, pharmaceutical development, to clinical trials (Choi et al., 2011). 
Large and global organizations as well as niche specialty groups are offering 
reduced costs, high flexibility, high level research premises and high quality 
services. cros are considered as a valuable source of innovation for Western 
pharmaceutical companies to develop strategic alliances to boost both re-
search and development of new products. At the same time, cros are eco-
nomic and effective way to buy «on demand» innovation.
5.4. Strategic asset seeking motivations: exploiting tcm products and practices
Part of the interest of key Western pharmaceutical companies into the 
Chinese market can also be related to the potentials of tcm (Shen, 2008, 
p. 22). Many Western countries have set up tcm institutions, including the 
United States, Europe, Japan and South Korea which are investing heavily in 
related research and medication development and industry (Shan, 2013).
Despite the increase popularity of alternative medicines in recent years 
around the world (Datamonitor, 2010, p. 15), Chinese companies do not 
have a primary role at world level. Local companies dominate the internal 
market (pwc, 2009, p. 4) and most of them have a low internationalization 
profile (Zhang, 2009; 2011): only about 3 percent of the global tcm market 
is in the Chinese’s hands. There is therefore huge space for partnership and 
alliances by Western companies that could help pushing the Chinese firm in 
the international arena. One of the key problems in expanding abroad is re-
lated to intellectual property rights, trademark registration and patent appli-
cations. Chinese companies are still weak in promoting their products on the 
global market (Zhang, 2011). 
5.5. Challenges and obstacles
Despite the great opportunities offered by the Chinese market, compared 
to weak sales growth in developed markets and revenue reduction because of 
competition from generics multinational firms, Western firms are encounter-
ing several problems in China. 
14 At the end of 2007 the value of r&d outsourced to China, mostly through cros, was 
worth 550 million dollars (Shen, 2008).
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As a result of slowdown in the Chinese economy and corruption scan-
dals, the market is still growing but at weaker rate (Armstrong, 2013) than 
in the past. In 2013, main revenues in the industry amounted to 355.4 billion 
dollars (+17.9 percent increase on a year basis) and pharmaceutical profits 
rose 17.6 percent (Xinhua, 2014).
The recent case of corruption against GlaxoSmithKline Plc is considered 
emblematic of the some new dynamics within the industry (Jourdan, Ruwitch 
2014). Foreign firms might have violated anti-corruption laws or artificially 
inflated drug prices, to be able to smooth business ties between sales repre-
sentatives and doctors. The State Administration for Industry and Commerce 
(saic), the country’s public security bureau (psb) and other local authori-
ties, are increasing their visits to foreign drug firms in search for evidence 
of crime (Jourdan, Ruwitch 2014). At the same time, the political pressure 
on policy makers is strong to address inequities and high costs of healthcare. 
This will probably bring additional public pressure on multinational firms to 
lower prices (Shobert, 2014)
Western drugmakers are also facing more intense competition from Chi-
nese firms. Foreign companies are more and more held to different standards 
than their domestic Chinese competitors (Shobert, 2014). The government 
wants to transform low-cost manufacturers of generics into companies capa-
ble of turning out branded medicines (Armstrong, 2013). The level of com-
petition is getting more and more intense.
6. innovation and patenting trends
To better understand industry dynamics, it is important to focus on inno-
vation and ip trends. Technological innovation achievements in the Chinese 
pharmaceutical market are remarkable. The Government has launched an in-
vestment campaign on innovation medicine, to support projects on «signifi-
cant new drug». Several state-level technical centers were opened as a result 
of some «Industry-University-Institute» cooperation programs. Innovative 
medicines (such as antofloxacin hydrochloride and recombinant helicobac-
ter pylori vaccine) were approved. Some monoclonal antibody agents (such 
as recombinant human tumor necrosis factor) had achieved industrialization. 
Breakthrough was made in cells culture in a large scale. The production tech-
nology of some products (such as amoxicillin and vitamin E) was enhanced. 
Achievements were made in the area of product and technology development 
(Ministry of Industry and Information Technology, 2012).
In such a flourishing environment, China has been very active in patent ap-
plications. According to the statistics from wipo in 2011, the quantity of Chi-
nese patent applications was increasing rapidly compared with other leading 
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countries. China applied 10,894 patents in 2010, which was 7 times of that in 
2000. China became the second largest patent application country in the phar-
maceutical domain after us exceeding Japan and German in 2005 (see tab. 7). 
Chinese enterprises have accelerated product registration also in developed 
markets. In 2013, Chinese medical companies submitted 150 files to the US 
Food and Drug Administration and 172 similar applications were submitted to 
the European Directorate for Quality Medicines reached (cccmhpie, 2014).
Considering the industrial sectors involved in patenting in China, from 
2000 to 2009, pharmaceutical has been on of the leading industrial sector for 
number of applications applied (tab. 8). 
Domestic firms lead the patent application ranking (see tab. 9). Taking 
medicine manufacturing industry as an example, there were only 273 pat-
ent applications in 1995, and this number increased to 8,601 in 2009. There 
were only 183 patents granted in 1995, and this number increased to 6,017 
in 2009. In the meantime, the patent applications and granted patents of 
foreign enterprises were also increasing. From 23 patent applications made 
by foreign enterprises in 1995, the number increased to 923 in 2009, while 
granted patents increased from 19 in 1995 to 986 in 2009. 
tab. 7. The pharmaceutical patent application by leading countries (2000-2009)
Year 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
The United States 
of America 9,989 11,386 15,069 16,877 18,584 21,872 22,155 21,884 20,957 19,497
China 1,347 2,509 3,445 4,178 4,689 8,385 9,578 11,157 10,962 10,894
Japan 2,949 3,240 3,814 4,514 5,112 5,528 5,694 5,358 5,165 5,297
Germany 2,708 2,990 3,965 4,428 4,727 5,236 4,814 4,229 3,899 3,649
Switzerland 854 1,129 1,504 1,993 2,598 2,991 2,839 3,098 3,332 2,992
France 1,647 1,667 1,875 1,881 2,134 2,159 2,174 2,234 2,326 2,488
Britain 1,933 1,866 1,944 2,122 2,306 2,268 2,203 2,215 2,184 2,103
The Republic of 
Korea 518 648 880 1,089 1,140 1,295 1,186 1,149 1,342 1,842
Source: wipo Statistics Database, 2011, based on the wipo ipc-Technology concordance table.
tab. 8. Patent applications published by field of Technology from 2000 to 2009, in China
Year 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Pharmaceuticals 1,347 2,509 3,445 4,178 4,689 8,385 9,578 11,157 10,962 10,894
Telecommunications 270 534 933 1,697 2,376 3,560 5,679 7,190 10,055 6,782
Computer technology 778 1,156 1,740 2,683 3,346 4,710 5,226 7,336 9,645 11,818
Biotechnology 428 2,570 2,198 1,343 1,561 2,329 2,472 2,787 3,873 4,574
Chemical engineering 428 578 692 1,053 1,131 1,877 2,191 2,884 4,061 4,785
Environmental 
technology
344 477 656 862 1,030 1,688 1,967 2,308 3,232 4,020
Source: wipo Statistics Database, 2011, based on the wipo ipc-Technology concordance table.
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Patents are becoming more and more popular also for tcm. The Chinese 
State Intellectual Property reported that since 1985, more than 68,000 tcm 
patents were registered. Over 66,000 of them were from domestic applicants 
(Jingjing, 2010). At the same time, China has applied for 3,000 tcm patents 
in foreign countries, but foreign countries applied for more than 10,000 tcm 
patents in China. Western firms do not appear to have a significant role in 
the database of Traditional Chinese Medicine patents (Spigarelli, Wei, 2012). 
The increasing role of foreign enterprises in patent applications and 
granted patents can be considered a combined consequence of improved ip 
protection made by the Government and of the booming pharmaceutical de-
mand in China (Xu, Shao 2013). 
The Government has adopted industrial and regulatory policies, such as 
preferential drug pricing and hospital drug procurement policies. The aim is 
to support research-based multinational firms and large domestic enterprises. 
At the same time, market access for foreign companies has been improved, 
also to strengthen intellectual property protection. A huge effort has been 
made also to regulate and approve active pharmaceutical ingredients and 
audit drug production facilities (Shen, 2008, p. 21). Anyway, there are also 
some evidence of growing protection of national interest, as in the case of the 
recently amended Chinese patent law. On May 1st 2012, a revised version of 
the Measures for the Compulsory Licensing for Patent Implementation came 
into effect. The amendment allows China to “issue compulsory licenses to eli-
tab. 9. Patent application and patent granted in Chinese manufacturing industry (1995-2000)
Year Total Foreign enterprises Foreign enterprises 
(proportion, %)
Patent 
application
Patent 
granted
Patent 
application
Patent 
granted
Patent 
application
Patent 
granted
1995 273 183 23 19 8.42 10.38
1996 168 113 67 54 39.88 47.79
1997 257 134 38 25 14.79 18.66
1998 275 224 95 62 34.55 27.68
1999 283 232 30 16 10.60 6.90
2000 547 414 87 168 15.90 40.58
2001 735 308 139 62 18.91 20.13
2002 999 484 70 64 7.01 13.22
2003 1,305 459 208 91 15.94 19.83
2004 1,696 902 354 145 20.87 16.08
2005 2,708 1,134 594 273 21.94 24.07
2006 2,383 1,965 575 495 24.13 25.19
2007 3,056 2,482 589 747 19.27 30.10
2008 3,917 3,170 863 853 22.03 26.91
2009 8,601 6,017 923 766 10.73 12.73
2010 5,767 5,672 841 986 14.58 17.38
Source: China Statistical Yearbook On High Technology Industry, several years.
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gible companies to produce generic versions of patented drugs during state 
emergencies, or unusual circumstances, or in the interests of the public. For 
«reasons of public health», eligible drug makers can also ask to export these 
medicines to other countries, including members of the World Trade Organi-
sation (Lyn, 2012). This legislation is considered a further proof that China 
is shaping its legal framework, to make use of legal space to produce generic 
drug.
7. conclusions
As the first research output of a wide European funded project on Eu-
rope-China cooperation in the healthcare sector, this paper assessed demand 
and supply-driven dynamics within the Chinese pharmaceutical industry. 
The Chinese pharmaceutical market is booming a result of several forces that 
have to do with demographic changes, improved living standards, and public poli-
cies. In particular, the Government has been embracing a large reform of the health-
care system to upgrade the quality and coverage of healthcare assistance by 2020. 
Chinese middle and upper classes are changing their attitude towards healthcare 
consumptions. Western medicines are now considered more effective then traditional 
Chinese medicine practices, especially as for life-saving drugs are concerned, antibi-
otics most of all.
From an industry perspective, the Chinese market seems to be evolving 
into a highly competitive marketplace, where Chinese firms are acting not 
only to keep market shares compared to Western firms, but also to conquer 
an active and strategic position in the global value chain. An r&d driven 
re-evolution of the market is taking place, thanks to the Government’s poli-
cies aiming at building a friendly environment for Western firms, attracted 
in China not only to be partners of local actors and grasp knowledge from 
them, but also to become customers of a more and more qualified r&d ori-
ented supply. At the same time, the Government is supporting the growth of 
global-national champions, reorganizing soes and pushing new private phar-
maceutical firms. The rise of Chinese innovative and large multinationals is 
promoted (Shen, 2008, p. 21).
Easier market access, revenue growth potentials, booming demand have 
been attracting in the last few years multinational pharmaceutical firms in 
China, looking for market opportunities to offset maturing patents and price 
pressures in their home markets (Shobert, 2014). Despite the potentials of 
the market, some relevant emerging pitfalls should be taken into considera-
tion by Western firms while assessing opportunities in China: 
– the Government is building a new Chinese life science sector, increas-
ing the level of innovation and promoting global competitiveness of the na-
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tional industry. The conditions of access and competition in the market for 
Western companies will be inevitably affected, in a pejorative sense;
– while China intends to develop a domestic life science sector, the gov-
ernment is promoting technology transfer programs between multinational 
firms, Chinese research institutions, local industry partners. Strategic alliance 
to promote spillover effects are involving Western firms (Di Tommaso, Huang 
2010; Barbieri et al., 2013). The question is whether the empowerment of Chi-
nese competitors will be adequately offset for Western firms – in terms of rev-
enues - and will allow them to safeguards global r&d investments;
– while a universal coverage is promoted, there is a growing public re-
sentment over inadequate healthcare. To face this situation, the Government 
is trying and re-direct public frustrations away from policy makers and to-
wards private, for-profit entities. Bribery cases and inspection campaigns for 
Western firms is considered a proof of this trend.
As a result of the industry analysis performed in the paper, further steps 
in the European-funded project will be developed. Researchers will: define 
the level of integration reached so far in the healthcare industries in Europe 
and China considering both trade, cooperation initiatives and investment 
flows; map European investments in the healthcare related industries; clarify 
obstacles, barriers and difficulties faced in initiating, maintaining and consoli-
dating business initiatives in China.
Some key implications can be highlighted for scholars involved in this 
research field. Government policies (ie. institutional factors) have a huge in-
fluence on composition, competition and evolution of industrial sectors in 
China, as they produce huge social, economic and industry shifts. In the case 
of the pharmaceutical sector, major impacts of government policy range from 
support to local firms towards new specialization (to upgrade their role in 
the value chain) and competitiveness (more effectiveness of patenting strat-
egies and encouraged globalization), to increased attractiveness of the local 
market to foreign investors. As Government policy vary consistently across 
sectors, assessing fdi or trade trends would require to consider the impact 
of such institutional voids. Very detailed sectoral level analysis is required in-
cluding in-depth focus on pharmaceuticals, tcm products, and medical de-
vices and equipment. General trends of trade and fdi in the healthcare sector 
might not be significant in the light of specific measures of intervention that 
affect sectoral dynamics. 
Entrepreneurs and policy makers should be aware of the highlighted 
trends in the Chinese market as well. The analysis has confirmed the tremen-
dous changes that China is experiencing in the approach to healthcare needs 
of the population. China is shifting towards a new universal healthcare sys-
tem. Among key changes to be promoted, there is the need to upgrade in-
dustry capabilities to produce healthcare products and to play an active role 
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in supplying solutions to the market. Western industries have reached a scale 
of efficiency, global competitiveness and sophisticated approaches to innova-
tion in the pharmaceutical sector (including medical devices, apparatus and 
instruments; hygiene materials; pharmaceutical machinery). China can there-
fore offer huge opportunities to «export» solutions, best practices and to 
create business opportunities. Specific policy (at country level) and business 
strategy could therefore tackle the Chinese request/eager in the healthcare 
sector. At the same time, pitfalls of the market, as described above, make the 
Chinese marketplace more and more challenging.
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